Patent · US Active

6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

US9758530B2 · kind B2 · utility

3Cited by

2References

14Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Lei Guo · Kowloon, CN
Taishan Hu · Shanghai, CN
Yimin Hu · Shanghai, CN
Buelent Kocer · Basel, CH
Buyu Kou · Shanghai, CN
Gangqin Li · Shanghai, CN
Xianfeng Lin · Shanghai, CN
Haixia Liu · Shanghai, CN
Hong Shen · Shanghai, CN
Houguang Shi · Shanghai, CN
Guolong Wu · Shanghai, CN
Zhisen Zhang · Shanghai, CN
Mingwei Zhou · Shanghai, CN
Wei Zhu · Shanghai, CN

Key dates

Filing date	Jan 8, 2016
Grant date	Sep 12, 2017
Priority date	—
Expiry date	Jan 8, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/506
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides novel compounds having the general formula:wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as or pharmaceutically acceptable salts, or tautomerism isomers, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.